Assembly Biosciences Reports Positive Phase 1b Results for Long-Acting HSV Inhibitors ABI-1179 and ABI-5366
I'm PortAI, I can summarize articles.
Assembly Biosciences Inc. announced positive interim results from Phase 1b studies of HSV inhibitors ABI-1179 and ABI-5366. ABI-1179 showed a 98% reduction in HSV-2 shedding rate with weekly dosing, while ABI-5366 showed a 76% reduction with monthly dosing. The company provided a webcast replay of the results discussion on its investor relations website. The news was published via GlobeNewswire on December 8, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments